An apolipoprotein E variant may protect against age-related macular degeneration through cytokine regulation.
about
The LOC387715 polymorphism and age-related macular degeneration: replication in three case-control samplesMilk metabolites and neurodegeneration: Is there crosstalk?Risk factors for age-related maculopathyRetinal ultrastructure of murine models of dry age-related macular degeneration (AMD).ApoE4 induces synaptic and ERG impairments in the retina of young targeted replacement apoE4 miceFunction and comorbidities of apolipoprotein e in Alzheimer's disease.Cross-talk between apolipoprotein E and cytokinesVariants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD.Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies.Immunopathological aspects of age-related macular degeneration.Vascular endothelial growth factor in eye disease.The HtrA1 promoter polymorphism, smoking, and age-related macular degeneration in multiple case-control samples.Review of genetics in age related macular degeneration.Normal aging involves modulation of specific inflammatory markers in the rat retina and choroid.Molecular pathology of age-related macular degenerationChlamydia pneumoniae infection, complement factor H variants and age-related macular degeneration.Mediators of ocular angiogenesis.Age-related macular degeneration: genetic and clinical findings.Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals.Genetic factors associated with age-related macular degeneration.
P2860
Q24678569-17D931EA-A457-4132-864F-D4D1DAD2E7F1Q26777352-5A7BB30E-22F3-4504-912A-66F2782B98BAQ33720834-1351B690-C6B2-430E-A35A-7BE159773466Q33787737-581CC46B-CC4E-4A12-8788-90CE4ECA6278Q34761039-1F32096B-8109-48C5-ACE3-51AA005E34CCQ34951817-9D61E723-4C65-46AE-95E2-6AA1CDD9AAB4Q35104765-226BD30D-E636-4C6F-BEA9-E8F36F19D33FQ35220974-3EC63E4A-0897-4318-8625-8A1B50F7E105Q35552553-1D852281-FD07-4566-94ED-3F21431E7FA6Q36739706-4B730C5E-4D86-4E8E-8C79-C8A52BBBDEF3Q36929380-472C2672-6C07-4676-B9DD-F7BDA931C779Q37030323-7A018279-470A-4289-BB14-2BE8CA992C70Q37039797-BE1D85CF-E026-4458-B61B-596801E0B9B2Q37126586-48360B59-7EFF-4AFB-94B5-F48A62ED7892Q37273740-6CEFB472-C06C-4FC8-9F04-49B7D962882EQ37353309-F2FC055C-B6B9-4D26-BF60-7F4B890DBF4EQ37678807-F476C028-2E05-43AC-A936-2AAA83F9ECD0Q37822792-F6302968-2393-4369-8617-EB6F0460A4B2Q37882685-4F92E098-3090-43F2-B765-5F90CC830893Q37901276-C891F700-33B8-4484-AFBF-15E6CF00DA4E
P2860
An apolipoprotein E variant may protect against age-related macular degeneration through cytokine regulation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
An apolipoprotein E variant ma ...... n through cytokine regulation.
@ast
An apolipoprotein E variant ma ...... n through cytokine regulation.
@en
type
label
An apolipoprotein E variant ma ...... n through cytokine regulation.
@ast
An apolipoprotein E variant ma ...... n through cytokine regulation.
@en
prefLabel
An apolipoprotein E variant ma ...... n through cytokine regulation.
@ast
An apolipoprotein E variant ma ...... n through cytokine regulation.
@en
P2093
P2860
P50
P356
P1476
An apolipoprotein E variant ma ...... on through cytokine regulation
@en
P2093
Baitang Ning
Christine M Bojanowski
Defen Shen
Karl G Csaky
W Richard Green
P2860
P304
P356
10.1002/EM.20233
P577
2006-10-01T00:00:00Z